Login to Your Account

TiGenix Merges with Cellerix in $79.7M All-Share Deal

By Nuala Moran

Monday, February 28, 2011
LONDON – TiGenix NV is merging with fellow cell therapy specialist Cellerix SA in an all-share deal valuing Cellerix at €58 million (US$79.7 million), creating a clear leader in the European regenerative medicine field, with two marketed products and a number of allogeneic adult stem cell therapies in clinical development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription